Richard Bloomfeld, MD

About Richard Bloomfeld

After finishing medical school at Washington University School of Medicine in St. Louis, Bloomfeld completed an internal medicine residency and gastroenterology fellowship at Duke University Medical Center, where he developed an interest in inflammatory bowel disease. In 2000, Bloomfeld joined Wake Forest School of Medicine’s section of gastroenterology to start an inflammatory bowel disease program offering comprehensive digestive disease care.

A practicing gastroenterologist, Bloomfeld’s expertise also extends to involvement in industry-sponsored clinical trials. He has longstanding experience as principal investigator of multicenter Phase 2 and Phase 3 clinical studies investigating the safety and efficacy of novel biologics for patients who have failed standard therapies. Recently, he participated in studies examining immunosuppressive treatments, stem-cell infusion and mucosal healing in patients with inflammatory bowel disease. He also leads several prospective drug trials, including evaluating HUMIRA® in patients with ulcerative colitis and researching the role of diet in disease.

Another area of Bloomfeld’s clinical expertise is treating recurrent C. difficile infections. He is currently involved in a Phase 3 clinical study exploring the treatment efficacy of oral fecal microbiota transplantation or oral stool transplant using capsules. He also has extensive experience leading gastrointestinal bleeding and colorectal cancer screening studies using virtual colonoscopy.

Bloomfeld has served on the board of directors of the North Carolina Society of Gastroenterology since 2014 and is a member of the Crohn’s and Colitis Foundation of America National Clinical Alliance. Through collaboration with industry partners nationwide, he leads studies evaluating the safety and efficacy of biologics for inflammatory bowel disease and conducts post-marketing registry studies for Federal Drug Administration approval.